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1. INTRODUCTION {#cam43018-sec-0005}
===============

Receiving a diagnosis of cancer and undergoing its subsequent treatments does not only have a detrimental impact on physical function, but may also affect psychological and social well‐being of the individual. Patient‐reported outcomes (PROs) addressing these domains of well‐being (including both physical and psychosocial components) are increasingly being incorporated in randomized controlled trials (RCTs) to assess the effectiveness of cancer treatments. A recent Cochrane systematic review on psychosocial well‐being and care needs of people with cancer [^1^](#cam43018-bib-0001){ref-type="ref"} concluded that there is a need not only for more uniformity in outcomes and reporting, but importantly also for combining PROs with objective clinical outcomes. These conclusions are also in line with a recent report of the US Food and Drug Administration and the Critical Path Institute---as they are "committed to collaborate with international drug development stakeholders to identify rigorous methods to incorporate the patient perspective into the development of cancer therapeutics."[^2^](#cam43018-bib-0002){ref-type="ref"}

In the context of prostate cancer (PCa), we have previously evaluated the completeness of PRO reporting of 65 RCTs published between January 2004 and March 2012, which reported on PROs.[^3^](#cam43018-bib-0003){ref-type="ref"} Significant improvements in PRO quality reporting over time were observed and it was estimated that about 20% of PRO RCTs had provided solid PRO data to allow health policy makers and clinicians to make a critical appraisal. Since 2012, over 800 new studies have been published on PCa and PROs, according to PubMed. Since then, PIONEER, an IMI2 funded pan‐European public private partnership led by the European Association of Urology (EAU), is in the process of defining core outcome sets for PCa in the context of the patient\'s treatment pathway---whereby PROs from RCTs as well as real world evidence will be included. Core outcome sets for PCa will provide homogeneity in clinician reported outcomes and patient‐reported outcomes measures (PROMs) (in terms of outcomes and their definitions) to help Guidelines Offices with summarizing study findings and generate evidence‐based recommendations for the PCa treatment pathway. PIONEER's goal is to ensure the optimal care for all European men diagnosed with PCa by unlocking the potential of "big data" and "big data analytics."[^4^](#cam43018-bib-0004){ref-type="ref"}, [^5^](#cam43018-bib-0005){ref-type="ref"}

Given the increasing importance of the use of PROs as part of "big data" in improving patient care,[^6^](#cam43018-bib-0006){ref-type="ref"} there is a need to provide evidence‐based PRO information that may be used to facilitate clinical decision‐making. The main objective of this study was to synthetize most recent high‐quality PRO data from PCa RCTs, that is, those studies most likely to robustly inform patient care through for example inclusion in the EAU PCa guidelines. The latter is a useful indication of quality of clinical studies with an impact on the PCa patient experience as these urological clinical guidelines are used worldwide to disseminate recommended PCa treatment pathways. The EAU PCa guidelines are updated on an annual basis using a broad and comprehensive literature search and are based on modified version of the Oxford Center for Evidence‐based Medicine Levels of Evidence. Any flaws in the evidence used to support any given recommendation are taken into account and hence reflect on the quality of PRO reported information. Details of the search methodology can be found here.[^7^](#cam43018-bib-0007){ref-type="ref"} A secondary objective of the current study was to assess whether completeness of PRO reporting in PCa research improved over time.

2. MATERIALS AND METHODS {#cam43018-sec-0006}
========================

2.1. Search strategy and identification of studies {#cam43018-sec-0007}
--------------------------------------------------

We conducted a systematic literature search using PubMed, from April 2012 until February 2019. Methodology for study identification and evaluation followed standardized criteria used in the Patient‐Reported Outcomes Measurements Over Time In Oncology (PROMOTION) Registry (<http://promotion.gimema.it>). Study abstracts and additional records identified through hand searching of the literature were screened by two independent reviewers, following study selection criteria (see further for additional details). Then, full‐text articles selected were assessed for eligibility. This was previously described in the systematic review on PROs in PCa RCTs covering the years 2004‐April, 2012.[^3^](#cam43018-bib-0003){ref-type="ref"} For the purpose of the current review, we used the same search terms as in our previous work[^3^](#cam43018-bib-0003){ref-type="ref"}: *(\"quality of life\" OR "health related quality of life" OR \"health status\" OR "health outcomes" OR "patient outcomes" OR "depression" OR "anxiety" OR "emotional" OR "social" OR "psychosocial" OR "psychological" OR "distress" OR "social functioning" OR "social wellbeing" OR "emotional" OR "patient reported symptom" OR \"patient reported outcomes\" OR pain OR fatigue OR "patient reported outcome" OR \"PRO\" OR \"PROs\" OR \"HRQL\" OR \"QOL\" OR \"HRQOL\" OR "symptom distress" OR "symptom burden" OR "symptom assessment" OR "functional status" OR sexual OR functioning) AND prostate*. The search strategy was restricted to RCTs. In case of multiple publications from the same RCT, all relevant data possibly published in secondary articles were combined.

2.2. Selection criteria {#cam43018-sec-0008}
-----------------------

Only English‐language reports of RCTs comparing conventional treatments and involving adult men with PCa were included---irrespective of disease stage. The minimum, overall sample size (combined treatment arms) was set at 50 patients. Screening studies or those involving patients with benign disease were excluded. We did not consider conference abstracts as these typically report insufficient information on PRO methodology and outcomes. RCTs of interventions that were psychological, behavioral, complementary, or alternative were also excluded.

We included all studies evaluating a PRO either as a primary or secondary endpoint---either as a multidimensional QoL outcome or a single dimensional outcome, such as symptoms. Those studies evaluating only treatment adherence or satisfaction were excluded. Details on search strategy and selection process were documented according to the PRISMA guidelines.[^8^](#cam43018-bib-0008){ref-type="ref"}

2.3. Methods of evaluation of studies {#cam43018-sec-0009}
-------------------------------------

Three reviewers (FS, LM, and KB) extracted information from the identified studies. Each study was evaluated independently by two of these reviewers. All data were entered by the reviewers into a password protected online database (REDCap)[^9^](#cam43018-bib-0009){ref-type="ref"} by completing a predefined electronic‐data extraction form (eDEF). Full details on information contained in the PROMOTION eDEF are reported in the appendix. A double‐blind data entry procedure was performed as each reviewer completed the eDEF independently. Discrepancies in evaluations were electronically recorded and when disagreements occurred in the evaluation of any item included in the eDEF, the reviewers revisited the paper to reconcile any differences. If no consensus was achieved, a fourth reviewer (FE) was consulted. For every included RCTs, their inclusion in the EAU PCa guidelines was checked by manual searches of the references and corresponding sections.

2.4. Type of data extraction and data analysis {#cam43018-sec-0010}
----------------------------------------------

For the purpose of this review, the following types of information were considered: (a) basic trial characteristics, (b) clinical and PRO characteristics, and (c) elements of PRO reporting based on recommendations from the International Society of Quality of Life Research (ISOQOL)[^10^](#cam43018-bib-0010){ref-type="ref"} and the CONSORT‐PRO extension.[^11^](#cam43018-bib-0011){ref-type="ref"} Quality of PRO reporting was evaluated with the ISOQOL checklist, which comprises a common set of 17 key issues regardless of PRO being a primary or secondary endpoint. Eleven additional issues were considered when a PRO was a primary endpoint of the study. Each item of the ISOQOL checklist was rated as "yes" if documented in the publication (scored as 1) or "no" if not documented (scored 0). To further refine the investigation of the accuracy of reporting, we divided the ISOQOL item addressing the problem of missing data into two (ie reporting the extent of missing data and reporting statistical approaches for dealing with missing data). We thus rated each RCT with a score ranging from 0 to a maximum of 18 (RCT with PRO as a secondary endpoint) or 29 (PRO as primary endpoint); in both cases, the higher the score the better the quality of the PRO reporting. Identification of high‐quality PRO studies was based on previously defined criteria.[^3^](#cam43018-bib-0003){ref-type="ref"} Specifically, we defined as high‐quality PRO studies those which, at the same time, satisfied at least two‐thirds of the recommended criteria (12 for RCT with PRO as secondary endpoint and 20 for PRO as primary endpoint) and addressed three mandatory issues: study patients characteristics and baseline PRO scores described, documentation of PRO instrument validity, and missing data reported. In addition, we checked whether those studies considered as high‐quality RCTs were included in the most recent EAU PCa Guidelines.[^12^](#cam43018-bib-0012){ref-type="ref"}, [^13^](#cam43018-bib-0013){ref-type="ref"}

Main characteristics of eligible studies (eg disease stage, type of PRO endpoint) were reported by proportions and means, according to the type of variable. Differences between studies were assessed using the chi‐square test. Based on the ISOQOL checklist score, comparisons between RCTs selected for this review and those included in a previous study[^3^](#cam43018-bib-0003){ref-type="ref"} were performed to examine whether the completeness of PRO reporting in PCa trials has improved over time. We also compared the overall level of PRO reporting according to the CONSORT‐PRO extension, between the RCTs published before and after the publication of this guideline. All tests were two‐sided and statistical significance was set at α = 0.05. Analyses were performed by SAS software v. 9.4 (SAS Institute Inc).

3. RESULTS {#cam43018-sec-0011}
==========

A total of 55 new RCTs were published between April 2012 and February 2019 (Figure [1](#cam43018-fig-0001){ref-type="fig"}), of which the majority were international trials (ie more than one country) (60%). An overview of trial characteristics, as compared to the data from January 2004 to March 2012 is shown in Table [1](#cam43018-tbl-0001){ref-type="table"}. The duration of PRO assessment has increased, with 63.6% of trials reporting a period of more than 1 year as compared to 43.1% of trials previously (*P* \< .006). Most RCTs reported on PROs as a secondary endpoint (70.9% vs 60% previously; *P* = .212). However, the prevalence of RCTs with a sample size ≥200 has increased over time, with 69.1% of RCTs including more than 200 men with PCa, as compared to 52.3% previously (*P* = .062).

![PRISMA flow chart of literature search results of Prostate Cancer Randomised Controlled Trials. PRO, patient‐reported outcomes](CAM4-9-4039-g001){#cam43018-fig-0001}

###### 

Overview of RCT characteristics as compared to our previous systematic review[^a^](#cam43018-note-0003){ref-type="fn"}

+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| Variable                                                                      | RCTs                           | RCTs                            | Total     | *P* value (two sided) |
|                                                                               |                                |                                 |           |                       |
|                                                                               | January 2004‐March 2012 (n=65) | April 2012‐February 2019 (n=55) | n (%)     |                       |
+===============================================================================+================================+=================================+===========+=======================+
| International (if more than one country)                                      |                                |                                 |           |                       |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| No                                                                            | 46 (70.8)                      | 22 (40)                         | 68 (56.7) | \<.001                |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| Yes                                                                           | 19 (29.2)                      | 33 (60)                         | 52 (43.3) |                       |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| Industry supported (fully or in part)                                         |                                |                                 |           |                       |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| No                                                                            | 31 (47.7)                      | 16 (29.1)                       | 47 (39.2) | .038                  |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| Yes                                                                           | 34 (52.3)                      | 39 (70.9)                       | 73 (60.8) |                       |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| Disease stage                                                                 |                                |                                 |           |                       |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| Only metastatic/advanced                                                      | 21 (32.3)                      | 27 (49.1)                       | 48 (40)   | .160                  |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| Only nonmetastatic/local                                                      | 31 (47.7)                      | 21 (38.2)                       | 52 (43.3) |                       |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| Both                                                                          | 13 (20)                        | 7 (12.7)                        | 20 (16.7) |                       |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| Secondary paper on PRO                                                        |                                |                                 |           |                       |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| No                                                                            | 47 (72.3)                      | 37 (67.3)                       | 84 (70)   | .549                  |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| Yes                                                                           | 18 (27.7)                      | 18 (32.7)                       | 36 (30)   |                       |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| Length of PRO assessment during RCT                                           |                                |                                 |           |                       |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| Up to 6 mo                                                                    | 22 (33.8)                      | 10 (18.2)                       | 32 (26.7) | .006                  |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| Up to 1 y                                                                     | 15 (23.1)                      | 6 (10.9)                        | 21 (17.5) |                       |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| More than 1 y                                                                 | 28 (43.1)                      | 35 (63.6)                       | 63 (52.5) |                       |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| Unknown                                                                       | 0 (0)                          | 4 (7.3)                         | 4 (3.3)   |                       |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| Overall study sample size                                                     |                                |                                 |           |                       |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| ≤200                                                                          | 31 (47.7)                      | 17 (30.9)                       | 48 (40)   | .062                  |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| \>200                                                                         | 34 (52.3)                      | 38 (69.1)                       | 72 (60)   |                       |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| Type of treatment used[^b^](#cam43018-note-0004){ref-type="fn"}               |                                |                                 |           |                       |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| Radiotherapy                                                                  | 21 (32.3)                      | 17 (30.9)                       | 38 (31.7) |                       |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| Surgery                                                                       | 10 (15.4)                      | 4 (7.3)                         | 14 (11.7) |                       |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| Chemotherapy                                                                  | 13 (20)                        | 10 (18.2)                       | 23 (19.2) |                       |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| Targeted therapy                                                              | 0 (0)                          | 12 (21.8)                       | 12 (10)   |                       |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| Hormonal therapy                                                              | 25 (38.5)                      | 24 (43.6)                       | 49 (40.8) |                       |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| Other                                                                         | 22 (33.9)                      | 4 (7.3)                         | 26 (21.7) |                       |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| PRO endpoint                                                                  |                                |                                 |           |                       |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| Primary                                                                       | 26 (40)                        | 16 (29.1)                       | 42 (35)   | .212                  |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| Secondary                                                                     | 39 (60)                        | 39 (70.9)                       | 78 (65)   |                       |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| Most frequently used PRO instruments[^b^](#cam43018-note-0004){ref-type="fn"} |                                |                                 |           |                       |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| EORTC Questionnaires                                                          | 18 (27.7)                      | 16 (29.1)                       | 34 (28.3) |                       |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| FACT Questionnaires                                                           | 13 (20)                        | 21 (38.2)                       | 34 (28.3) |                       |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| BPI                                                                           | 5 (7.7)                        | 13 (23.6)                       | 18 (15)   |                       |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| VAS or LASA Questionnaires                                                    | 8 (12.3)                       | 3 (5.5)                         | 11 (9.2)  |                       |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| IPSS                                                                          | 2 (3.1)                        | 7 (12.7)                        | 9 (7.5)   |                       |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| SF‐36 Questionnaires                                                          | 2 (3.1)                        | 6 (10.9)                        | 8 (6.7)   |                       |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| EPIC                                                                          | 0 (0)                          | 7 (12.7)                        | 7 (5.8)   |                       |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+
| EQ‐5D                                                                         | 1 (1.5)                        | 5 (9.1)                         | 6 (5)     |                       |
+-------------------------------------------------------------------------------+--------------------------------+---------------------------------+-----------+-----------------------+

Abbreviations: BPI, Brief Pain Inventory; EORTC, European Organization for Research and Treatment of cancer; EPIC, Expanded Prostate Cancer Index Composite; EQ‐5D, EuroQol‐5 Dimensions; FACT, Functional Assessment of Cancer Therapy; LASA, Linear Analog Scale Assessment; PRO, Patient‐Reported Outcomes; RCT, Randomized Controlled Trial; VAS, Visual Analog Scale.
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To assess the clinical impact of the RCTs, we first identified the proportion of high‐quality RCTs with respect to PRO reporting, which was 43.6%, an increase since 2012 when it was 20% (*P* \< .01). Table [2](#cam43018-tbl-0002){ref-type="table"} provides more information about these high‐quality RCTs (n = 47 reports---describing study results of 24 different RCTs). The majority of trials (15/24) were conducted in the advanced PCa setting (ie locally advanced PCa, metastatic PCa, metastatic castration‐resistant and nonmetastatic castration‐resistant PCa). Some RCTs included patients with different PCa stages, so that it was not possible to categorize these RCTs according to localized, locally advanced, or metastatic PCa. Six studies focussed exclusively on men with localized PCa. In these high‐quality RCTs, PROs encompassed Health‐Related Quality of Life (HRQoL) or symptoms such as erectile, bladder, or bowel function. The most frequently used measures were Functional Assessment of Cancer Therapy‐Prostate (FACT‐P) (9/24), EORTC QLQ‐C30 and/or its module QLQ‐PR25 (5/24), and Expanded Prostate Cancer Index Composite (EPIC) (5/24).

###### 

Patient‐Reported Outcomes (PROs) and PRO measurements (PROMs) in the high‐quality PRO RCTs for prostate cancer

+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| Name of study                                                               | First author                                        | PCa risk category                                                                                                                                       | PRO                                                                                       | PROM                                           |
+=============================================================================+=====================================================+=========================================================================================================================================================+===========================================================================================+================================================+
| PREVAIL, 2015                                                               | Loriot [^27^](#cam43018-bib-0027){ref-type="ref"}   | mCRPC                                                                                                                                                   | HRQoL                                                                                     | FACT‐P                                         |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | Pain                                                                                      | EQ‐5D                                          |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           | Brief Pain Inventory Short                     |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| PREVAIL, 2014[^a^](#cam43018-note-0006){ref-type="fn"}                      | Beer[^28^](#cam43018-bib-0028){ref-type="ref"}      | mCRPC                                                                                                                                                   | QoL                                                                                       | FACT‐P                                         |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| PREVAIL, 2017                                                               | Devlin[^29^](#cam43018-bib-0029){ref-type="ref"}    | mCRPC                                                                                                                                                   | HRQoL                                                                                     | EQ‐5D                                          |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| REACTT, 2015                                                                | Patel[^30^](#cam43018-bib-0030){ref-type="ref"}     | Nonmetastatic PCa (GS ≤ 7, PSA \< 10)                                                                                                                   | Erectile function                                                                         | IIEF‐EF                                        |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | Patients' treatment satisfaction                                                          | EDITS questionnaire                            |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | Self‐esteem (baseline)                                                                    | SEAR questionnaire                             |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | Prostate‐specific QoL                                                                     | EPIC‐26                                        |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| REACTT, 2013                                                                | Montorsi[^31^](#cam43018-bib-0031){ref-type="ref"}  | Nonmetastatic PCa (GS ≤ 7, PSA \< 10)                                                                                                                   | Erectile Function                                                                         | IIEF‐EF score                                  |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | Sexual encounter                                                                          | SEP‐1/ SEP‐2 questions                         |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| RTOG‐0126, 2015                                                             | Bruner[^32^](#cam43018-bib-0032){ref-type="ref"}    | cT1b‐2b, (+GS2‐6, PSA10‐20 OR GS7, PSA \< 15)                                                                                                           | Bladder function                                                                          | FACE questionnaire                             |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | Bowel function                                                                            | FACE questionnaire                             |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | Erectile function                                                                         | IIEF questionnaire                             |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| RTOG‐0126, 2013                                                             | Michalski[^33^](#cam43018-bib-0033){ref-type="ref"} | cT1b‐2b, (+GS2‐6, PSA10‐20 OR GS7, PSA \< 15)                                                                                                           | Acute GI/GU toxicity                                                                      | RTOG/EORTC late morbidity scoring system       |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | Late GI/GU toxicity                                                                       |                                                |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| RTOG‐0126, 2018[^a^](#cam43018-note-0006){ref-type="fn"}                    | Michalski[^34^](#cam43018-bib-0034){ref-type="ref"} | cT1b‐2b, (+GS2‐6, PSA10‐20 OR GS7, PSA \< 15)                                                                                                           | /                                                                                         | /                                              |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| AFFIRM, 2014                                                                | Fizazi[^35^](#cam43018-bib-0035){ref-type="ref"}    | mCRCP                                                                                                                                                   | Pain                                                                                      | BPI‐SF                                         |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | HRQoL improvement                                                                         | FACT‐P                                         |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | HRQoL deterioration                                                                       | FACT‐P                                         |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| AFFIRM, 2015                                                                | Cella[^36^](#cam43018-bib-0036){ref-type="ref"}     | mCRPC                                                                                                                                                   | HRQoL                                                                                     | FACT‐P                                         |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| AFFIRM, 2012[^a^](#cam43018-note-0006){ref-type="fn"}                       | Scher[^37^](#cam43018-bib-0037){ref-type="ref"}     | mCRPC                                                                                                                                                   | QoL                                                                                       | FACT‐P                                         |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| AFFIRM, 2017                                                                | Armstrong[^38^](#cam43018-bib-0038){ref-type="ref"} | mCRPC                                                                                                                                                   | /                                                                                         | /                                              |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| COU‐AA‐302 phase 3, 2013                                                    | Basch[^39^](#cam43018-bib-0039){ref-type="ref"}     | mCRPC                                                                                                                                                   | Pain                                                                                      | BPI‐SF questionnaire                           |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | HRQoL                                                                                     | FACT‐P questionnaire                           |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| COU‐AA‐302 phase 3, 2012[^a^](#cam43018-note-0006){ref-type="fn"}           | Ryan[^40^](#cam43018-bib-0040){ref-type="ref"}      | mCRPC                                                                                                                                                   | HRQoL                                                                                     | FACT‐P                                         |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | Pain                                                                                      | BPI‐SF                                         |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| PROTECT, 2013                                                               | Beer[^41^](#cam43018-bib-0041){ref-type="ref"}      | Nonmetastatic androgen dependent PCa with PSA relapse and GS ≥ 7 after RP                                                                               | QoL                                                                                       | BFI score                                      |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           | LASA score, GRoC scale, symptoms checklist     |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| PROTECT, 2011                                                               | Beer[^42^](#cam43018-bib-0042){ref-type="ref"}      | Nonmetastatic androgen dependent PCa with PSA relapse and GS ≥ 7 after RP                                                                               | /                                                                                         | /                                              |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| SWOG‐9346, 2013[^a^](#cam43018-note-0006){ref-type="fn"}                    | Hussain[^43^](#cam43018-bib-0043){ref-type="ref"}   | mCRPC                                                                                                                                                   | HRQoL                                                                                     | QoL questionnaire (SWOG)                       |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| NR                                                                          | Mason[^44^](#cam43018-bib-0044){ref-type="ref"}     | T2b‐T4N0M0, GS ≥ 7, or PSA ≥ 10                                                                                                                         | LUTS relief                                                                               | IPSS                                           |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | QoL (urinary symptoms)                                                                    |                                                |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| TROG 03.04 RADAR, 2012                                                      | Denham[^18^](#cam43018-bib-0018){ref-type="ref"}    | cT2b--4N0M0 or T2a + GS≥7 + PSA≥10                                                                                                                      | QoL                                                                                       | EORTC QLQ‐C30 + EORTC QLQ‐PR‐25 questionnaires |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| TROG 03.04 RADAR, 2014                                                      | Denham[^45^](#cam43018-bib-0045){ref-type="ref"}    | cT2b--4N0M0 or T2a + GS≥7 + PSA≥10                                                                                                                      | /                                                                                         | /                                              |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| TROG 03.04 RADAR, 2012                                                      | Denham[^46^](#cam43018-bib-0046){ref-type="ref"}    | cT2b--4N0M0 or T2a + GS≥7 + PSA≥10                                                                                                                      | Dysfunctional rectal symptoms                                                             | EORTC QLQ‐PR25 questionnaire                   |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| NCT00884273, 2012                                                           | Axcrona[^47^](#cam43018-bib-0047){ref-type="ref"}   | PCa all stages                                                                                                                                          | LUTS relief                                                                               | IPSS                                           |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | QoL improvement                                                                           |                                                |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| CHHiP, 2015[^a^](#cam43018-note-0006){ref-type="fn"}                        | Wilkins[^17^](#cam43018-bib-0017){ref-type="ref"}   | pT1b--T3aN0M0                                                                                                                                           | Overall bowel bother                                                                      | UCLA‐PCI, EPIC instrument                      |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | Overall urinary bother                                                                    | FACT‐P, SF‐36, SF‐12                           |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | Overall sexual bother                                                                     |                                                |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | General HRQoL                                                                             |                                                |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| CHHiP, 2016[^a^](#cam43018-note-0006){ref-type="fn"}                        | Dearnaley[^48^](#cam43018-bib-0048){ref-type="ref"} | pT1b--T3aN0M0                                                                                                                                           | Patient reported outcome                                                                  | UCLA‐PCI, EPIC instrument                      |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| ACTRN12611000661976[^a^](#cam43018-note-0006){ref-type="fn"}                | Yaxley[^15^](#cam43018-bib-0015){ref-type="ref"}    | ≤T2cN0M0                                                                                                                                                | Urinary function                                                                          | EPIC score                                     |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | Sexual function                                                                           | EPIC/ IIEF score                               |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | Pain                                                                                      | Surgical pain scale                            |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | Physical and mental functioning                                                           | SF‐36                                          |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | Fatigue                                                                                   | Vitality domain SF‐36                          |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | Bowel function                                                                            | EPIC score                                     |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | Cancer‐specific distress                                                                  | RIES scale                                     |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | Psychological distress                                                                    | HADS score                                     |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | Time to return to work                                                                    | /                                              |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| NCT00866554                                                                 | Gaudet[^49^](#cam43018-bib-0049){ref-type="ref"}    | T1c‐T2b, GS: 6 or 7(3 + 4), PSA ≤ 15                                                                                                                    | Acute and late effects on sexual function                                                 | IPSS + EPIC score                              |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | Urinary toxicity                                                                          | IPSS + EPIC score                              |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| TROG 03.06 and VCOG PR 01‐03, 2017                                          | Duchesne[^50^](#cam43018-bib-0050){ref-type="ref"}  | PSA relapse after treatment or group two of asymptomatic men unsuitable for curative treatment because of age, comorbidity, or locally advanced disease | Global HRQoL                                                                              | EORTC QLQ‐C30, EORTC QLQ‐PR25                  |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| TROG 03.06 and VCOG PR 01‐03, 2016[^a^](#cam43018-note-0006){ref-type="fn"} | Dushesne[^51^](#cam43018-bib-0051){ref-type="ref"}  | PSA relapse after treatment or group two of asymptomatic men unsuitable for curative treatment because of age, comorbidity, or locally advanced disease | Global HRQoL                                                                              | EORTC QLQ‐C30, EORTC QLQ‐PR25                  |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| MRC PATCH trial (PR09), 2016                                                | Gilbert[^52^](#cam43018-bib-0052){ref-type="ref"}   | cT3‐4cN + M0 or TxNxM1                                                                                                                                  | Global health status/QoL                                                                  | EORTC QLQ‐C30,                                 |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | Urinary, bowel and sexual symptoms and function and hormone‐related symptoms              | QLQ‐PR25                                       |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| MRC PATCH trial (PR09), 2013                                                | Langley[^53^](#cam43018-bib-0053){ref-type="ref"}   | cT3‐4cN + M0 or TxNxM1                                                                                                                                  | Adverse events (not patient reported)                                                     | Not applicable                                 |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| MRC PATCH trial (PR09), 2016                                                | Langley[^54^](#cam43018-bib-0054){ref-type="ref"}   | cT3‐4cN + M0 or TxNxM1                                                                                                                                  | /                                                                                         | /                                              |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| ASCENDE‐RT trial, 2016                                                      | Rodda[^55^](#cam43018-bib-0055){ref-type="ref"}     | High‐risk PCa: T3aN0M0, GS 8‐9, PSA \> 20                                                                                                               | HRQoL                                                                                     | SF36v2                                         |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| ASCENDE‐RT trial, 2013[^a^](#cam43018-note-0006){ref-type="fn"}             | Morris[^56^](#cam43018-bib-0056){ref-type="ref"}    | High‐risk PCa: T3aN0M0, GS 8‐9, PSA \> 20                                                                                                               | /                                                                                         | /                                              |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| PROSPER, 2018[^a^](#cam43018-note-0006){ref-type="fn"}                      | Hussain[^57^](#cam43018-bib-0057){ref-type="ref"}   | nmCRPC                                                                                                                                                  | QoL assessments                                                                           | /                                              |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| PROSPER, 2019                                                               | Tombal[^58^](#cam43018-bib-0058){ref-type="ref"}    | nmCRPC                                                                                                                                                  | Pain progression                                                                          | BPI‐SF questionnaire                           |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | HRQoL                                                                                     | EORTC QLQ‐PR25                                 |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| RTOG 0938, 2018                                                             | Lukka[^59^](#cam43018-bib-0059){ref-type="ref"}     | Low risk PCa (cT1‐2aN0M0, PSA \< 10, GS 2‐6)                                                                                                            | Bowel and urinary PROs                                                                    | EPIC‐50                                        |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | \% of patients with \>5 point reduction in the EPIC bowel domain at 1 y                   | EPIC 50                                        |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | \% of patients with \>2 point reduction in EPIC urinary domain at 1 y                     | EPIC 50                                        |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | Sexual and hormonal toxicity                                                              | EPIC 50                                        |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | Acute/Late GI/GU toxicity                                                                 | EPIC 50                                        |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| COMET‐2, 2018                                                               | Basch[^60^](#cam43018-bib-0060){ref-type="ref"}     | mCRPC                                                                                                                                                   | Rate of pain response                                                                     | BPI reports                                    |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| SPARTAN, 2018                                                               | Saad[^16^](#cam43018-bib-0016){ref-type="ref"}      | nmCRPC                                                                                                                                                  | HRQoL: PCa symptoms, pain‐related symptoms, and overall QoL                               | EQ‐5D‐3L                                       |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | HRQoL: mobility, self‐care, usual activities, pain, discomfort, and anxiety or depression | FACT‐P                                         |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| SPARTAN, 2018[^a^](#cam43018-note-0006){ref-type="fn"}                      | Smith[^61^](#cam43018-bib-0061){ref-type="ref"}     | nmCRPC                                                                                                                                                  | /                                                                                         | /                                              |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| NCT 02135357, 2018                                                          | Khalaf[^62^](#cam43018-bib-0062){ref-type="ref"}    | mCRPC                                                                                                                                                   | Patient reported HRQoL                                                                    | FACT‐P                                         |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | Depression symptoms                                                                       | PHQ‐9                                          |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | Cognitive function                                                                        | MoCA                                           |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| NCT 02135357, 2018                                                          | Annala[^63^](#cam43018-bib-0063){ref-type="ref"}    | mCRPC                                                                                                                                                   | /                                                                                         | /                                              |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| SWOG S0421, 2018                                                            | Unger[^64^](#cam43018-bib-0064){ref-type="ref"}     | mCRPC                                                                                                                                                   | Palliation of worst pain                                                                  | BPI inventory                                  |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | Improvement of functional status                                                          | FACT‐P TOI                                     |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | Vitality                                                                                  | SF‐36 Energy/vitality scale                    |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | General QoL                                                                               | EORTC QLQ‐C30                                  |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | Analgesic use                                                                             | (Pain medication logs)                         |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| SWOG S0421, 2013                                                            | Quinn[^65^](#cam43018-bib-0065){ref-type="ref"}     | mCRPC                                                                                                                                                   | /                                                                                         | /                                              |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| CHAARTED, 2015[^a^](#cam43018-note-0006){ref-type="fn"}                     | Sweeney[^66^](#cam43018-bib-0066){ref-type="ref"}   | Metastatic hormone‐sensitive PCa                                                                                                                        | /                                                                                         | /                                              |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| CHAARTED, 2018                                                              | Morgans[^67^](#cam43018-bib-0067){ref-type="ref"}   | Metastatic hormone‐sensitive PCa                                                                                                                        | Overall QoL                                                                               | FACT‐P                                         |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | Treatment and disease‐related QoL                                                         | FACT‐Taxane                                    |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | Adverse effect of taxanes treatment                                                       | FACIT‐Fatigue                                  |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | Fatigue                                                                                   | BPI                                            |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | Pain                                                                                      |                                                |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| LATITUDE, 2017[^a^](#cam43018-note-0006){ref-type="fn"}                     | Fizazi[^68^](#cam43018-bib-0068){ref-type="ref"}    | Metastatic hormone‐sensitive PCa                                                                                                                        | Time to pain progression                                                                  | BPI‐SF                                         |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+
| LATITUDE, 2018                                                              | Chi[^69^](#cam43018-bib-0069){ref-type="ref"}       | Metastatic hormone‐sensitive PCa                                                                                                                        | Pain                                                                                      | BPI‐SF                                         |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | Fatigue                                                                                   | BFI                                            |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | Disease‐related QoL                                                                       | FACT‐P                                         |
|                                                                             |                                                     |                                                                                                                                                         |                                                                                           |                                                |
|                                                                             |                                                     |                                                                                                                                                         | HRQoL                                                                                     | EQ‐5D‐5L                                       |
+-----------------------------------------------------------------------------+-----------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+------------------------------------------------+

Abbreviations: BPI, Brief Pain Inventory; EDITS, Erectile Dysfunction Inventory of Treatment Satisfaction; EORTC QLQ‐C30, European Organization for Research and Treatment of Cancer Quality of life questionnaire‐Core 30; EORTC QLQ‐PR25, European Organization for Research and Treatment of Cancer Quality of life questionnaire‐Prostate 25; EPIC, Expanded Prostate Index Composite questionnaire; EQ‐5D, EuroQol 5‐dimension; EQ‐5D‐3L, EuroQol 5‐dimension, 3‐level questionnaire; FACE, Functional Alterations due to Changes in Elimination; FACT‐P, Functional assessment of Cancer Therapy‐Prostate Cancer; HADS, Hospital Anxiety and Depression Scale; IIEF‐EF, International Index of Erectile Function‐Erectile Function; IPSS, International Prostate Symptom Score; MoCA, Montreal Cognitive Assessment;PHQ‐9, Patient Health Questionnaire‐9; RIES, Revised Impact of Events; SEAR, Self‐Esteem and Relationship questionnaire; SF‐36, Short‐Form 36; UCLA‐PCI, UCLA Prostate Cancer Index.

Included in the EAU prostate cancer guidelines.

John Wiley & Sons, Ltd

To further assess the clinical impact of these RCTs, Table [3](#cam43018-tbl-0003){ref-type="table"} reports on the influence of the reported HRQoL on the final treatment recommendation (as defined by the authors of each published RCT). As most RCTs reported clinical and HRQoL specific outcomes separately, Table [3](#cam43018-tbl-0003){ref-type="table"} aims to combine the results as one final recommendation for each RCT. In the metastatic PCa group, new treatment options (ie second‐generation antiandrogens like enzalutamide and abiraterone) and the use of docetaxel resulted in significant improvements in both clinical (overall, progression‐free, and metastatic‐free survival) and HRQoL outcomes.

###### 

Evaluation of HRQoL outcomes/recommendations for included high‐quality PROs

+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Name of trial                                                                                                                                                                              | Treatment                                                                                                                                   | HRQoL outcome                                                                                                                                                                                                                              | Clinical outcome                                                                              | Treatment recommendations                                                                                                                                                                     |
+============================================================================================================================================================================================+=============================================================================================================================================+============================================================================================================================================================================================================================================+===============================================================================================+===============================================================================================================================================================================================+
| PREVAIL\*                                                                                                                                                                                  | Enzalutamide (160 mg/d) vs placebo                                                                                                          | Enza: reduced risk of and delayed time to HRQoL deterioration, pain progression, and occurrence of SREs.                                                                                                                                   |                                                                                               | Enza is recommended in asymptomatic and minimally symptomatic, chemo‐naïve patients with mCRPC due to its positive effects on survival and HRQoL benefits.                                    |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Loriot[^27^](#cam43018-bib-0027){ref-type="ref"}                                                                                                                                           |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Beer[^28^](#cam43018-bib-0028){ref-type="ref"}                                                                                                                                             |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Devlin[^29^](#cam43018-bib-0029){ref-type="ref"}                                                                                                                                           |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
|                                                                                                                                                                                            | Significant delay in radiographic disease progression or death and need for cytotoxic chemotherapy                                          |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Significant benefits in terms of Pain/Discomfort and Anxiety/Depression (EQ‐5D)                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| REACTT                                                                                                                                                                                     | 9 mo tadalafil 5 mg once daily vs tadalafil 20 mg on demand vs placebo                                                                      | Early chronic dosing after nsRP increases and accelerates EF recovery and improves patients' QoL.                                                                                                                                          |                                                                                               | Tadalafil treatment may contribute to the recovery of EF after RP                                                                                                                             |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Patel[^30^](#cam43018-bib-0030){ref-type="ref"}                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Montorsi[^31^](#cam43018-bib-0031){ref-type="ref"}                                                                                                                                         |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Improvements in IIEF‐EF and successful intercourse during 9 mo tadalafil once daily were not sustained 6w after drug cessation.                                                            | Protection from penile length loss                                                                                                          |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| RTOG‐0126\*                                                                                                                                                                                | 3D‐CRT vs IMRT                                                                                                                              | No difference in patient‐reported bowel, bladder, or sexual functions                                                                                                                                                                      |                                                                                               | The decision to deliver high radiation dose must be balanced against the risk of morbidity in the individual patient.                                                                         |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Bruner[^32^](#cam43018-bib-0032){ref-type="ref"}                                                                                                                                           |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Michalski[^33^](#cam43018-bib-0033){ref-type="ref"}                                                                                                                                        |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Michalski[^34^](#cam43018-bib-0034){ref-type="ref"}                                                                                                                                        |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| IMRT: Lower incidence of acute GI or GU toxicity and a lower cumulative incidence of late grade 2b rectal toxicity                                                                         |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Increase in late grade 2 or greater GI and GU toxic effects.                                                                                                                               | Improvement in biochemical failure and distant metastases, but no improvement in OS.                                                        |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| AFFIRM\*                                                                                                                                                                                   | Enzalutamide (160 mg/d) vs placebo                                                                                                          | Reduction of the risk of SREs. Reduction of pain and increase in time to HRQoL deterioration                                                                                                                                               |                                                                                               | Enza improves both OS and well‐being and everyday functioning of patients with mCRPC (postchemo)                                                                                              |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Fizazi[^35^](#cam43018-bib-0035){ref-type="ref"}                                                                                                                                           |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Cella[^36^](#cam43018-bib-0036){ref-type="ref"}                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Scher[^37^](#cam43018-bib-0037){ref-type="ref"}                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Armstrong[^38^](#cam43018-bib-0038){ref-type="ref"}                                                                                                                                        |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Stabilization of patient HRQoL                                                                                                                                                             |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
|                                                                                                                                                                                            | Prolonged OS                                                                                                                                |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
|                                                                                                                                                                                            | PSA declines of any, ≥30%, and ≥50% within 90 d of Enza were strongly associated with the clinical benefit                                  |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| COU‐AA‐302 phase 3\*                                                                                                                                                                       | Abiraterone acetate + prednisone vs prednisone alone                                                                                        | Delay in patient‐reported pain progression and HRQoL deterioration                                                                                                                                                                         |                                                                                               | Abi + prednisone can be recommended for patients with mCRPC (prechemo)                                                                                                                        |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Basch[^39^](#cam43018-bib-0039){ref-type="ref"}                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Ryan[^40^](#cam43018-bib-0040){ref-type="ref"}                                                                                                                                             |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
|                                                                                                                                                                                            | Improvement of radiographic PFS, a trend toward improvement of OS, and significant delay in clinical decline and initiation of chemotherapy |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| PROTECT                                                                                                                                                                                    | Sipuleucel‐T vs placebo                                                                                                                     | No clinically significant negative impact on QoL                                                                                                                                                                                           |                                                                                               | Long‐term FU is needed to determine the effect on clinically important events                                                                                                                 |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Beer[^41^](#cam43018-bib-0041){ref-type="ref"}                                                                                                                                             |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Beer[^42^](#cam43018-bib-0042){ref-type="ref"}                                                                                                                                             |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
|                                                                                                                                                                                            | No difference in biochemical failure                                                                                                        |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| SWOG‐9346, 2013\*                                                                                                                                                                          | Intermittent vs continuous ADT                                                                                                              | Intermittent therapy was associated with improved EF and mental health at 3 mo but not thereafter.                                                                                                                                         | Too few events occurred to rule out significant inferiority of intermittent therapy           | In this noninferiority trial, findings were statistically inconclusive                                                                                                                        |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Hussain[^43^](#cam43018-bib-0043){ref-type="ref"}                                                                                                                                          |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| NR                                                                                                                                                                                         | Degarelix + RT vs Goserelin with bicalutamide + RT                                                                                          | Degarelix had more pronounced effects on LUTS in symptomatic patients                                                                                                                                                                      | Noninferior efficacy of degarelix in terms of prostate shrinkage                              | Degarelix provides an alternative treatment for PCa patients who need neoadjuvant ADT before RT, especially for those having LUTS problems.                                                   |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Mason[^44^](#cam43018-bib-0044){ref-type="ref"}                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| TROG 03.04 RADAR                                                                                                                                                                           | STAS (6 mo) vs STAS + ZA vs ITAS (12 mo) vs ITAS + ZA                                                                                       | ITAS + RT causes adverse effects on some PROs but not on global QoL scores. Only hormone treatment‐related symptoms persisted at marginally higher frequencies. HDR‐BT boost adversely affected emotional function and financial problems. |                                                                                               | Further follow‐up of the RADAR trial is needed before we can take our findings to the clinic                                                                                                  |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Denham[^18^](#cam43018-bib-0018){ref-type="ref"}                                                                                                                                           |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Denham[^45^](#cam43018-bib-0045){ref-type="ref"}                                                                                                                                           |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Denham[^46^](#cam43018-bib-0046){ref-type="ref"}                                                                                                                                           |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
|                                                                                                                                                                                            | No difference in PCa‐specific mortality between the 4 groups                                                                                |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| ADT, ZA and increasing EBRT dose did not increase rectal or urinary dysfunction. The use of HDR‐BT increased urinary dysfunction.                                                          |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| NCT00884273                                                                                                                                                                                | 12 wk of degarelix (240/80 mg) vs goserelin                                                                                                 | Degarelix showed superiority in LUTS relief in symptomatic patients                                                                                                                                                                        | Same reduction in total prostate volume                                                       | Degarelix can be considered as a useful approach to combined GnRH agonist plus antiandrogen for PCa patients in need of short‐term neoadjuvant ADT.                                           |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Axcrona[^47^](#cam43018-bib-0047){ref-type="ref"}                                                                                                                                          | (3.6 mg) + 28 d of bicalutamide.                                                                                                            |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| CHHiP\*                                                                                                                                                                                    | Hypofractionated RT vs conventional RT                                                                                                      | PROs were not significantly different between treatment groups for any of the endpoints                                                                                                                                                    |                                                                                               | Hypofractionated RT using 60 Gy in 20 fractions is recommended as new standard of care for EBRT of localized PCa.                                                                             |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Wilkins[^17^](#cam43018-bib-0017){ref-type="ref"}                                                                                                                                          |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Dearnaley[^48^](#cam43018-bib-0048){ref-type="ref"}                                                                                                                                        |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
|                                                                                                                                                                                            | Hypofractionated schedule is noninferior to the conventionally fractionated schedule for time to biochemical or clinical failure            |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| ACTRN12611000661976\*                                                                                                                                                                      | RARP vs RRP                                                                                                                                 | No difference in domain‐specific QoL outcomes at 12 wk                                                                                                                                                                                     | No difference in pathological outcomes at 12 wk                                               | Long‐term follow‐up is needed                                                                                                                                                                 |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Yaxley[^15^](#cam43018-bib-0015){ref-type="ref"}                                                                                                                                           |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| NCT00866554                                                                                                                                                                                | Dutasteride 0.5 mg + Bicalutamide 50 mg + Tamoxifen 10 mg daily vs LHRH agonist + Bicalutamide daily                                        | Less sexual toxicity compared to LHRH agonists prior to BT and for the first 6 mo after BT                                                                                                                                                 | Noninferior efficacy to LHRH agonist based regimens for prostate volume reduction prior to BT | D + B is therefore an option to be considered for prostate volume reduction prior to BT                                                                                                       |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Gaudet[^49^](#cam43018-bib-0049){ref-type="ref"}                                                                                                                                           |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| TROG 03.06 and VCOG PR 01‐03\*                                                                                                                                                             | Immediate vs delayed ADT (PSA relapse only)                                                                                                 | Early detriments in specific hormone treatment‐related symptoms with immediate ADT, but with no other demonstrable effect on overall functioning or HRQoL                                                                                  |                                                                                               | Progression is delayed, but at a small cost in global QoL. The option can be discussed with men with a PSA relapse.                                                                           |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Duchesne[^50^](#cam43018-bib-0050){ref-type="ref"}                                                                                                                                         |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| G Dushesne [^51^](#cam43018-bib-0051){ref-type="ref"}                                                                                                                                      |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
|                                                                                                                                                                                            | Immediate receipt of ADT significantly improved OS                                                                                          |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| MRC PATCH trial (PR09)                                                                                                                                                                     | Transdermal estradiol vs LHRH agonist                                                                                                       | estradiol: better self‐reported QoL outcomes at 6 mo but increased gynecomastia                                                                                                                                                            |                                                                                               | Provides further supporting evidence for the ongoing phase 3 trial                                                                                                                            |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Gilbert[^52^](#cam43018-bib-0052){ref-type="ref"}                                                                                                                                          |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Langley[^53^](#cam43018-bib-0053){ref-type="ref"}                                                                                                                                          |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| RE Langley [^54^](#cam43018-bib-0054){ref-type="ref"}                                                                                                                                      |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
|                                                                                                                                                                                            | Castrate testosterone concentrations similar to those achieved with LHRHa                                                                   |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Mitigating BMD loss                                                                                                                                                                        | Castration levels of testosterone comparable with LHRHa administration                                                                      |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| ASCENDE‐RT trial\*                                                                                                                                                                         | LDR‐BT vs DE‐EBRT                                                                                                                           | LDR‐PB boost: more moderate to severe GU toxicity, urinary incontinence, and need for catheterization and a larger mean decline in HRQoL for physical and urinary function at 6 y.                                                         |                                                                                               | Treatment should be individualized and requires careful consideration of the potential risks and benefits.                                                                                    |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Rodda[^55^](#cam43018-bib-0055){ref-type="ref"}                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Morris[^56^](#cam43018-bib-0056){ref-type="ref"}                                                                                                                                           |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
|                                                                                                                                                                                            | LDR‐PB patients were twice as likely to be free of BF at a median follow‐up of 6.5 y                                                        |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| PROSPER\*                                                                                                                                                                                  | Enzalutamide vs placebo                                                                                                                     |                                                                                                                                                                                                                                            | Significantly increased metastasis‐free survival                                              | Enza is a treatment option that should be discussed in high‐risk, nmCRPC                                                                                                                      |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Hussain[^57^](#cam43018-bib-0057){ref-type="ref"}                                                                                                                                          |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Tombal[^58^](#cam43018-bib-0058){ref-type="ref"}                                                                                                                                           |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Benefit in delaying pain progression, symptom worsening, and decrease in functional status                                                                                                 |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| RTOG 0938, 2018                                                                                                                                                                            | Two ultrahypofractionated RT schemes                                                                                                        | Both schemes are well tolerated and bowel, urinary, and sexual PROs are comparable to those for standard RT                                                                                                                                |                                                                                               | Longer follow‐up is required                                                                                                                                                                  |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Lukka[^59^](#cam43018-bib-0059){ref-type="ref"}                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| COMET‐2, 2018                                                                                                                                                                              | Cabozantinib vs mitoxantrone‐prednisone                                                                                                     | Cabozantinib treatment did not improve pain palliation                                                                                                                                                                                     |                                                                                               | Enrollment was terminated                                                                                                                                                                     |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Basch[^60^](#cam43018-bib-0060){ref-type="ref"}                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| SPARTAN\*                                                                                                                                                                                  | Apalutamide vs placebo                                                                                                                      | HRQoL was maintained after initiation of apalutamide treatment                                                                                                                                                                             |                                                                                               | Apalutamide provides clinical benefit in the treatment of men with nmCRPC                                                                                                                     |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Saad[^16^](#cam43018-bib-0016){ref-type="ref"}                                                                                                                                             |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| MR Smith [^61^](#cam43018-bib-0061){ref-type="ref"}                                                                                                                                        |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
|                                                                                                                                                                                            | Metastasis‐free survival and time to symptomatic progression were significantly longer                                                      |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| NCT 02135357                                                                                                                                                                               | Abiraterone vs enzalutamide                                                                                                                 | PROs favored Abi with differences in FACT‐P and PHQ‐9 scores. Differences in the total FACT‐P score only in the elderly subgroup.                                                                                                          |                                                                                               | Abi and Enza are standard first‐line treatment options for mCRPC with similar efficacy but different side‐effect profiles. Administration should be discussed with each patient individually. |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Khalaf[^62^](#cam43018-bib-0062){ref-type="ref"}                                                                                                                                           |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Annala[^63^](#cam43018-bib-0063){ref-type="ref"}                                                                                                                                           |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
|                                                                                                                                                                                            | Enza: superior PSA responses but no differences in progression‐free survival                                                                |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| CHAARTED\*                                                                                                                                                                                 | ADT + Docetaxel vs ADT alone                                                                                                                |                                                                                                                                                                                                                                            | Six cycles of docetaxel at the beginning of ADT resulted in significantly OS than ADT alone.  | For patients with hormone‐sensitive metastatic PCa, who are fit enough ADT + docetaxel can be considered                                                                                      |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Sweeney[^66^](#cam43018-bib-0066){ref-type="ref"}                                                                                                                                          |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Morgans[^67^](#cam43018-bib-0067){ref-type="ref"}                                                                                                                                          |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Both arms reported a similar minimally changed QoL over time, suggesting that ADT + Docetaxel is not associated with a greater long‐term negative impact on QoL                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| LATITUDE\*                                                                                                                                                                                 | ADT + abiraterone acetate + prednisone vs ADT alone                                                                                         |                                                                                                                                                                                                                                            | Addition of abiraterone acetate increased OS and radiographic progression‐free survival       | Treatment with ADT plus abiraterone acetate and prednisone could be considered a new option for standard of care for patients with metastatic castration‐naïve PCa                            |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Fizazi[^68^](#cam43018-bib-0068){ref-type="ref"}                                                                                                                                           |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Chi[^69^](#cam43018-bib-0069){ref-type="ref"}                                                                                                                                              |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Addition of abiraterone acetate improved overall PROs by consistently showing a clinical benefit in the progression of pain, PCa symptoms, fatigue, functional decline, and overall HRQoL. |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| SWOG S0421                                                                                                                                                                                 | Docetaxel + Atrasentan vs Docetaxel + placebo                                                                                               | No substantial treatment arm differences for pain and functional status                                                                                                                                                                    |                                                                                               | Docetaxel remains one of the standard options for CRPC. Endothelin inhibitors do not have an established role.                                                                                |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Unger[^64^](#cam43018-bib-0064){ref-type="ref"}                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
|                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
| Quinn[^65^](#cam43018-bib-0065){ref-type="ref"}                                                                                                                                            |                                                                                                                                             |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
|                                                                                                                                                                                            | Atrasentan did not improve PFS or OS                                                                                                        |                                                                                                                                                                                                                                            |                                                                                               |                                                                                                                                                                                               |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+

John Wiley & Sons, Ltd

To date, 14 of the 47 publications have been included in the EAU PCa Guidelines[^12^](#cam43018-bib-0012){ref-type="ref"}, [^13^](#cam43018-bib-0013){ref-type="ref"}---reflecting 13 different RCTs (Table [2](#cam43018-tbl-0002){ref-type="table"}).

In terms of methodology, there was still a lack of information on mode of administration of the PRO tool and methods of data collection over time (83.6% vs 76.9%; *P* = .360). However, there was an improvement in the reporting of the evidence for PRO instrument validity and reliability (80% vs 66.1%; *P* = .007). More RCTs also identified PROs in the trial protocol and post hoc analyses (67.3% vs 20%; *P* \< .001). In general, there was an improvement in terms of reporting methods and results for PROs in PCa RCTs. A detailed overview of the methodological assessment, as compared to our previous systematic review,[^3^](#cam43018-bib-0003){ref-type="ref"} is provided in Table [4](#cam43018-tbl-0004){ref-type="table"}.

###### 

Level of patient‐reported outcomes (PRO) reporting as compared to our previous systematic review[^3^](#cam43018-bib-0003){ref-type="ref"}

+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Variable                                                                                                                                                                                                                                                                          | Category                                       | RCTs                               | RCTs                                | Total     | *P* value (two sided) |
|                                                                                                                                                                                                                                                                                   |                                                |                                    |                                     |           |                       |
|                                                                                                                                                                                                                                                                                   |                                                | January 2004‐March 2012 n = 65 (%) | April 2012‐February 2019 n = 55 (%) | n (%)     |                       |
+===================================================================================================================================================================================================================================================================================+================================================+====================================+=====================================+===========+=======================+
| **Title and abstract**                                                                                                                                                                                                                                                            |                                                |                                    |                                     |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| The PRO is identified as an outcome in the abstract                                                                                                                                                                                                                               | No                                             | 6 (9.2)                            | 4 (7.3)                             | 10 (8.3)  | .699                  |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Yes                                                                                                                                                                                                                                                                               | 59 (90.8)                                      | 51 (92.7)                          | 110 (91.7)                          |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| (Additional standards only for PRO as primary outcome) The title of the paper is explicit as to the RCT including a PRO[^a^](#cam43018-note-0007){ref-type="fn"}                                                                                                                  | No                                             | 10 (38.5)                          | 9 (56.3)                            | 19 (45.2) | .252                  |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Yes                                                                                                                                                                                                                                                                               | 16 (61.5)                                      | 7 (43.8)                           | 23 (54.8)                           |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| **Introduction, background, and objectives**                                                                                                                                                                                                                                      |                                                |                                    |                                     |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| The PRO hypothesis is stated and should specify the relevant PRO domain if applicable                                                                                                                                                                                             | No                                             | 11 (16.9)                          | 19 (34.5)                           | 30 (25)   | .082                  |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Yes                                                                                                                                                                                                                                                                               | 24 (36.9)                                      | 15 (27.3)                          | 39 (32.5)                           |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| N/A (if explorative)                                                                                                                                                                                                                                                              | 30 (46.2)                                      | 21 (38.2)                          | 51 (42.5)                           |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| (Additional standards only for PRO as primary outcome) The introduction contains a summary of PRO research that is relevant to the RCT[^a^](#cam43018-note-0007){ref-type="fn"}                                                                                                   | No                                             | 3 (11.5)                           | 7 (43.7)                            | 10 (23.8) | .031                  |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Yes                                                                                                                                                                                                                                                                               | 23 (88.5)                                      | 9 (56.3)                           | 32 (76.2)                           |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| (Additional standards only for PRO as primary outcome) Additional details regarding the hypothesis are provided including the rationale for the selected domains, the expected directions of change, and the time points for assessment.[^a^](#cam43018-note-0007){ref-type="fn"} | No                                             | 22 (84.6)                          | 12 (75)                             | 34 (81)   | .346                  |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Yes                                                                                                                                                                                                                                                                               | 4 (15.4)                                       | 4 (25)                             | 8 (19)                              |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| **Methods**                                                                                                                                                                                                                                                                       |                                                |                                    |                                     |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| *Outcomes*                                                                                                                                                                                                                                                                        |                                                |                                    |                                     |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| The mode of administration of the PRO tool and the methods of collecting data are described                                                                                                                                                                                       | No                                             | 50 (76.9)                          | 46 (83.6)                           | 96 (80)   | .360                  |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Yes                                                                                                                                                                                                                                                                               | 15 (23.1)                                      | 9 (16.4)                           | 24 (20)                             |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Electronic mode of PRO administration                                                                                                                                                                                                                                             | No                                             | 15 (23.1)                          | 5 (9.1)                             | 20 (16.7) | .044                  |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Yes                                                                                                                                                                                                                                                                               | 0 (0)                                          | 2 (3.6)                            | 2 (1.6)                             |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| N/A                                                                                                                                                                                                                                                                               | 50 (76.9)                                      | 48 (87.3)                          | 98 (81.7)                           |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| The rationale for choice of the PRO instrument used is provided                                                                                                                                                                                                                   | No                                             | 24 (36.9)                          | 26 (47.3)                           | 50 (41.7) | .252                  |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Yes                                                                                                                                                                                                                                                                               | 41 (63.1)                                      | 29 (52.7)                          | 70 (58.3)                           |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Evidence of PRO instrument validity and reliability is provided or cited                                                                                                                                                                                                          | No                                             | 22 (33.9)                          | 11 (20)                             | 33 (27.5) | .007                  |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Yes, for all PRO instruments                                                                                                                                                                                                                                                      | 25 (38.4)                                      | 37 (67.3)                          | 62 (51.7)                           |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Yes, only for some PRO instruments                                                                                                                                                                                                                                                | 18 (27.7)                                      | 7 (12.7)                           | 25 (20.8)                           |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| The intended PRO data collection schedule is provided                                                                                                                                                                                                                             | No                                             | 6 (9.2)                            | 5 (9.1)                             | 11 (9.2)  | .979                  |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Yes                                                                                                                                                                                                                                                                               | 59 (90.8)                                      | 50 (90.9)                          | 109 (90.8)                          |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| PROs are identified in the trial protocol; post hoc analyses are identified                                                                                                                                                                                                       | No                                             | 52 (80)                            | 18 (32.7)                           | 70 (58.3) | \<.001                |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Yes                                                                                                                                                                                                                                                                               | 13 (20)                                        | 37 (67.3)                          | 50 (41.7)                           |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| The status of PRO as either a primary or secondary outcome is stated                                                                                                                                                                                                              | No                                             | 9 (13.8)                           | 3 (5.5)                             | 12 (10)   | .106                  |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Yes                                                                                                                                                                                                                                                                               | 48 (73.9)                                      | 49 (89)                            | 97 (80.8)                           |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Unclear                                                                                                                                                                                                                                                                           | 8 (12.3)                                       | 3 (5.5)                            | 11 (9.2)                            |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| (Additional standards only for PRO as primary outcome) A citation for the original development of the PRO instrument is provided[^a^](#cam43018-note-0007){ref-type="fn"}                                                                                                         | No                                             | 11 (42.3)                          | 3 (18.8)                            | 14 (33.3) | .086                  |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Yes                                                                                                                                                                                                                                                                               | 7 (26.9)                                       | 10 (62.4)                          | 17 (40.5)                           |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Yes, only for some PRO instruments                                                                                                                                                                                                                                                | 8 (30.8)                                       | 3 (18.8)                           | 11 (26.2)                           |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| (Additional standards only for PRO as primary outcome) Windows for valid PRO responses are specified and justified as being appropriate for the clinical context[^a^](#cam43018-note-0007){ref-type="fn"}                                                                         | No                                             | 7 (26.9)                           | 14 (87.5)                           | 21 (50)   | \<.001                |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Yes                                                                                                                                                                                                                                                                               | 19 (73.1)                                      | 2 (12.5)                           | 21 (50)                             |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| *Sample size*                                                                                                                                                                                                                                                                     |                                                |                                    |                                     |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| (Additional standards only for PRO as primary outcome) There is a power sample size calculation relevant to the PRO based on a clinical rationale[^a^](#cam43018-note-0007){ref-type="fn"}                                                                                        | No                                             | 10 (38.5)                          | 5 (31.2)                            | 15 (35.7) | .412                  |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Yes                                                                                                                                                                                                                                                                               | 16 (61.5)                                      | 11 (68.8)                          | 27 (64.3)                           |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| *Statistical methods*                                                                                                                                                                                                                                                             |                                                |                                    |                                     |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| There is evidence of appropriate statistical analysis and tests of statistical significance for each PRO hypothesis tested                                                                                                                                                        | No                                             | 2 (3.1)                            | 3 (5.5)                             | 5 (4.2)   | .418                  |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Yes                                                                                                                                                                                                                                                                               | 22 (33.8)                                      | 13 (23.6)                          | 35 (29.2)                           |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| N/A (If PRO hypotheses were not stated)                                                                                                                                                                                                                                           | 41 (63.1)                                      | 39 (70.9)                          | 80 (66.6)                           |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| The extent of missing data is stated                                                                                                                                                                                                                                              | No                                             | 18 (27.7)                          | 17 (30.9)                           | 35 (29.2) | .699                  |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Yes                                                                                                                                                                                                                                                                               | 47 (72.3)                                      | 38 (69.1)                          | 85 (70.8)                           |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Statistical approaches for dealing with missing data are explicitly stated                                                                                                                                                                                                        | No                                             | 53 (81.5)                          | 35 (63.6)                           | 88 (73.3) | .027                  |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Yes                                                                                                                                                                                                                                                                               | 12 (18.5)                                      | 20 (36.4)                          | 32 (26.7)                           |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| (Additional standards only for PRO as primary outcome) The manner in which multiple comparisons have been addressed is provided[^a^](#cam43018-note-0007){ref-type="fn"}                                                                                                          | No                                             | 19 (73.1)                          | 11 (68.8)                           | 30 (71.4) | .439                  |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Yes                                                                                                                                                                                                                                                                               | 7 (26.9)                                       | 5 (31.2)                           | 12 (28.6)                           |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| **Results**                                                                                                                                                                                                                                                                       |                                                |                                    |                                     |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| *Participant flow*                                                                                                                                                                                                                                                                |                                                |                                    |                                     |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| A flow diagram or a description of the allocation of participants and those lost to follow‐up is provided for PROs specifically                                                                                                                                                   | No                                             | 41 (63.1)                          | 24 (43.6)                           | 65 (54.2) | .033                  |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Yes                                                                                                                                                                                                                                                                               | 24 (36.9)                                      | 31 (56.4)                          | 55 (45.8)                           |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| The reasons for missing data are explained                                                                                                                                                                                                                                        | No                                             | 42 (64.6)                          | 37 (67.3)                           | 79 (65.8) | .760                  |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Yes                                                                                                                                                                                                                                                                               | 23 (35.4)                                      | 18 (32.7)                          | 41 (34.2)                           |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| *Baseline data*                                                                                                                                                                                                                                                                   |                                                |                                    |                                     |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| The study patients characteristics are described including baseline PRO scores                                                                                                                                                                                                    | No                                             | 23 (35.4)                          | 14 (25.5)                           | 37 (30.8) | .241                  |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Yes                                                                                                                                                                                                                                                                               | 42 (64.6)                                      | 41 (74.5)                          | 83 (69.2)                           |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| *Outcomes and estimation*                                                                                                                                                                                                                                                         |                                                |                                    |                                     |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Are PRO outcomes also reported in a graphical format?                                                                                                                                                                                                                             | No                                             | 26 (40)                            | 15 (27.3)                           | 41 (34.2) | .143                  |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Yes                                                                                                                                                                                                                                                                               | 39 (60)                                        | 40 (72.7)                          | 79 (65.8)                           |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| (Additional standards only for PRO as primary outcome) The analysis of PRO data accounts for survival differences between treatment groups if relevant[^a^](#cam43018-note-0007){ref-type="fn"}                                                                                   | No                                             | 1 (3.8)                            | 1 (6.2)                             | 2 (4.8)   | .002                  |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Yes                                                                                                                                                                                                                                                                               | 0 (0)                                          | 7 (43.8)                           | 7 (16.6)                            |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| N/A (if not relevant)                                                                                                                                                                                                                                                             | 25 (96.2)                                      | 8 (50)                             | 33 (78.6)                           |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| (Additional standards only for PRO as primary outcome) Results are reported for all PRO domains(if multidimensional)and items identified by the reference instrument[^a^](#cam43018-note-0007){ref-type="fn"}                                                                     | No                                             | 3 (11.5)                           | 7 (43.7)                            | 10 (23.8) | .031                  |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Yes                                                                                                                                                                                                                                                                               | 23 (88.5)                                      | 9 (56.3)                           | 32 (76.2)                           |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| (Additional standards only for PRO as primary outcome) The proportion of patients achieving predefined responder definitions is provided where relevant[^a^](#cam43018-note-0007){ref-type="fn"}                                                                                  | No                                             | 1 (3.9)                            | 3 (18.7)                            | 4 (9.5)   | .198                  |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Yes                                                                                                                                                                                                                                                                               | 7 (26.9)                                       | 2 (12.5)                           | 9 (21.4)                            |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| N/A (if not relevant)                                                                                                                                                                                                                                                             | 18 (69.2)                                      | 11 (68.8)                          | 29 (69.1)                           |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| **Discussion**                                                                                                                                                                                                                                                                    |                                                |                                    |                                     |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| *Limitations*                                                                                                                                                                                                                                                                     |                                                |                                    |                                     |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| The limitations of the PRO components of the trial are explicitly discussed                                                                                                                                                                                                       | No                                             | 42 (64.6)                          | 33 (60)                             | 75 (62.5) | .603                  |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Yes                                                                                                                                                                                                                                                                               | 23 (35.4)                                      | 22 (40)                            | 45 (37.5)                           |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| *Generalizability*                                                                                                                                                                                                                                                                |                                                |                                    |                                     |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Generalizability issues uniquely related to the PRO results are discussed                                                                                                                                                                                                         | No                                             | 28 (43.1)                          | 26 (47.3)                           | 54 (45)   | .645                  |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Yes                                                                                                                                                                                                                                                                               | 37 (56.9)                                      | 29 (52.7)                          | 66 (55)                             |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| *Interpretation*                                                                                                                                                                                                                                                                  |                                                |                                    |                                     |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Are PRO interpreted?(Not only restated)                                                                                                                                                                                                                                           | No                                             | 19 (29.2)                          | 12 (21.8)                           | 31 (25.8) | .355                  |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Yes                                                                                                                                                                                                                                                                               | 46 (70.8)                                      | 43 (78.2)                          | 89 (74.2)                           |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| The clinical significance of the PRO findings is discussed                                                                                                                                                                                                                        | No                                             | 44 (67.7)                          | 35 (63.6)                           | 79 (65.8) | .641                  |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Yes                                                                                                                                                                                                                                                                               | 21 (32.3)                                      | 20 (36.4)                          | 41 (34.2)                           |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Methodology used to assess clinical significance                                                                                                                                                                                                                                  | Anchor based (eg minimal important difference) | 15 (23.1)                          | 13 (23.6)                           | 28 (23.3) | .251                  |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Distribution based (e.g effect size)                                                                                                                                                                                                                                              | 6 (9.2)                                        | 3 (5.5)                            | 9 (7.5)                             |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Both                                                                                                                                                                                                                                                                              | 0 (0)                                          | 3 (5.5)                            | 3 (2.5)                             |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Other                                                                                                                                                                                                                                                                             | 0 (0)                                          | 1 (1.8)                            | 1 (0.8)                             |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Missing                                                                                                                                                                                                                                                                           | 44 (67.7)                                      | 35 (63.6)                          | 79 (65.9)                           |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| The PRO results is discussed in the context of the other clinical trial outcomes                                                                                                                                                                                                  | No                                             | 4 (6.1)                            | 15 (27.3)                           | 19 (15.8) | .002                  |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Yes                                                                                                                                                                                                                                                                               | 61 (93.9)                                      | 40 (72.7)                          | 101 (84.2)                          |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| **Other information**                                                                                                                                                                                                                                                             |                                                |                                    |                                     |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| *Protocol*                                                                                                                                                                                                                                                                        |                                                |                                    |                                     |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| (Additional standards only for PRO as primary outcome) A copy of the instrument is included if it has not been published previously (It could be found in the article appendix or in the online version of the paper)[^a^](#cam43018-note-0007){ref-type="fn"}                    | No                                             | 13 (50)                            | 2 (12.5)                            | 15 (35.7) | \<.001                |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| Yes                                                                                                                                                                                                                                                                               | 13 (50)                                        | 0 (0)                              | 13 (31)                             |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+
| N/A (if the instrument is already published or known in the literature)                                                                                                                                                                                                           | 0 (0)                                          | 14 (87.5)                          | 14 (33.3)                           |           |                       |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+------------------------------------+-------------------------------------+-----------+-----------------------+

Percentage for these items was calculated by considering only the RCTs with PRO as primary endpoint (n = 42), that is, 26 RCTs published between January 2004 and March 2012 and 16 RCTs published from April 2012 to February 2019.

John Wiley & Sons, Ltd

Evaluating the level of PRO reporting according to the CONSORT‐PRO extension, we observed, for all of the items, an improvement in the studies published after the publication of the CONSORT‐PRO extension, compared with those published before. Major differences were observed in two key items: the statistical methods for dealing with missing data were reported in 36.6% of newer RCTs as compared to 21.5% of older RCTs and PRO‐specific limitations were discussed in 46.3% vs 32.9% of RCTs, respectively (Table [5](#cam43018-tbl-0005){ref-type="table"}).

###### 

Level of PRO reporting by year (2013) of publication of the CONSORT‐PRO extension

+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+---------------------------------------------------------+
| CONSORT‐PRO Extension Item                                                                                                                                                                                                                          | RCTs before CONSORT‐PRO publication (2004‐2013) (n = 79) | RCTs after CONSORT‐PRO publication (2014‐2019) (n = 41) |
|                                                                                                                                                                                                                                                     |                                                          |                                                         |
|                                                                                                                                                                                                                                                     | No (%)                                                   | No (%)                                                  |
+=====================================================================================================================================================================================================================================================+==========================================================+=========================================================+
| P1b. The PRO should be identified in the abstract as a primary or secondary outcome.                                                                                                                                                                | 72 (91.1)                                                | 38 (92.7)                                               |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+---------------------------------------------------------+
| P2b. The PRO hypothesis should be stated, and relevant domains should be identified if applicable.[^a^](#cam43018-note-0009){ref-type="fn"}                                                                                                         | 25 (31.7)                                                | 14 (34.2)                                               |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+---------------------------------------------------------+
| P6a. Evidence of PRO instrument validity and reliability should be provided or cited if available.[^b^](#cam43018-note-0010){ref-type="fn"}                                                                                                         | 55 (69.6)                                                | 32 (78.0)                                               |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+---------------------------------------------------------+
| P6aa. This is the mode of administration, including the person completing the PRO and the methods of data collection (paper, telephone, electronic, and other).[^b^](#cam43018-note-0010){ref-type="fn"}, [^c^](#cam43018-note-0011){ref-type="fn"} | 15 (19.0)                                                | 9 (22.0)                                                |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+---------------------------------------------------------+
| P12a. Statistical approaches for dealing with missing data are explicitly stated.                                                                                                                                                                   | 17 (21.5)                                                | 15 (36.6)                                               |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+---------------------------------------------------------+
| P20/21. PRO‐specific limitations and implications for generalizability and clinical practice should be discussed.                                                                                                                                   | 26 (32.9)                                                | 19 (46.3)                                               |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+---------------------------------------------------------+

Abbreviations: CONSORT, Consolidated Standards of Reporting Trials; PRO, patient‐reported outcome; RCT, randomized controlled trial.

This percentage was calculated on the basis of all studies (including those explicitly reporting an exploratory evaluation, for which this item would be rated as not applicable).

Items P6a and P6aa were combined in the original CONSORT‐PRO extension; however, for the purposes of this study, to better appraise the proportion of RCTs providing evidence on the validity of the PRO instrument but not further describing how this was administered to patients, this item was split into two items.

In case of studies using multiple PRO measures, we evaluated this as "yes" if at least one measure was validated.

John Wiley & Sons, Ltd

4. DISCUSSION {#cam43018-sec-0012}
=============

Between April 2012 and February 2019, a total of 55 PCa RCTs have been published using PRO, of which nearly half (43.6%) can be considered as high‐quality RCTs for use of PROs. Of these 24 trials, only 13 (54.2%) have been reported in the most recent EAU Guidelines for PCa. The majority of RCTs were conducted in the advanced and metastatic PCa setting. Six RCTs were specifically conducted in men with localized PCa. Overall QoL and erectile, urinary, and bowel function were the most commonly reported PRO. The FACT‐P, EPIC‐26, and EORTC QLQ‐C30 and/or QLQ‐PR25 were the most commonly used measurement tools. An overall improvement in the reporting of the evidence for PROs was noted.

As highlighted by Kluetz et al cancer clinical trials have mainly focused on overall survival and measures of tumor growth or reduction to assess the efficacy of a specific treatment.[^14^](#cam43018-bib-0014){ref-type="ref"} However, the balance between improving disease symptoms and introducing symptomatic toxicity affects how patients function in their daily lives and hence affects their HRQoL. Kluetz and colleagues suggest to focus on three distinct measures of well‐defined concepts: symptomatic adverse events, physical function, and disease‐related symptoms. As shown in Table [2](#cam43018-tbl-0002){ref-type="table"}, these outcomes are measured in several of the included PCa RCTs, however, only the ACTRN12611000[^15^](#cam43018-bib-0015){ref-type="ref"} and the SPARTAN[^16^](#cam43018-bib-0016){ref-type="ref"} trials specifically reported on all three outcomes.

It is important to note that the majority of trials used validated tools, with FACT‐P, EPIC‐26, and EORTC QLQ‐C30 being the most commonly used. Those studies that were included in the EAU guidelines had all used at least one of these three measurement tools. However, these validated HRQoL questionnaires were less common in trials of men with localized PCa. The latter focused more on specific adverse events such as erectile or bowel function. Nevertheless, the CHHiP trial measured general HRQoL with FACT‐P[^17^](#cam43018-bib-0017){ref-type="ref"} and the TROG 03.04 RADAR trial measured QoL with EORTC QLQ‐C30 and its PCa module.[^18^](#cam43018-bib-0018){ref-type="ref"}

There seems to be a need for PRO‐specific guidance for the different disease‐specific stages of PCa. There are emerging international standards[^19^](#cam43018-bib-0019){ref-type="ref"} to help generate robust data with more focus on patient engagement and the EAU is already undertaking work to develop core outcome sets for PCa, including both clinician‐reported outcomes and PROs.[^4^](#cam43018-bib-0004){ref-type="ref"}, [^5^](#cam43018-bib-0005){ref-type="ref"}, [^20^](#cam43018-bib-0020){ref-type="ref"} With improved methodology and practice, and increasing patient engagement, high quality and clinically meaningful generation of PRO data will become the norm for PCa clinical studies[^21^](#cam43018-bib-0021){ref-type="ref"} and help increase their clinical impact in every disease stage. This will ensure that more high‐quality PRO studies will also be incorporated in the recommendations of guidelines offices, which also uses robust evidence assessment methods. A modified Grading of Recommendations Assessment, Development and Evaluation (GRADE) is currently used by the EAU. This approach allows for a transparent assessment of how recommendation statements have been developed, whereby overall quality of the evidence along with magnitude of effect, certainty of the results, balance between desirable and undesirable outcomes, impact of patient values, and preferences on the intervention, and certainty of those patient values and preferences result in guideline recommendations.[^7^](#cam43018-bib-0007){ref-type="ref"} Inclusion of PRO studies into the guidelines thus provides a reflection on the quality of the evidence and the reporting of PROs.

It is important to note that a patient‐centred treatment recommendation should consider both clinical (ie survival) and HRQoL outcomes. Considering these HRQoL aspects relies on understanding patients' values, needs, and experience of the disease and integrate them to formulate an optimal treatment strategy. Quality of life remains subjective and validated PROMs are of critical importance to guide these tailored interventions to improve patients' well‐being. The rising importance of PROs is already captured for localized disease by a systematic review, coordinated by the EAU PCa Guidelines panel, evaluating the effect of primary treatment on HRQoL.[^22^](#cam43018-bib-0022){ref-type="ref"} The same PROMs as reported in our systematic review were captured, emphasizing their importance and systematic use. Such evaluation and recommendations are lacking for advanced and metastatic disease, where HRQoL becomes even more important. Methodology for reporting of PRO and HRQoL for these different disease stages does not need to differ, but there is a clear need for a broader consensus on its use in all disease stages so that it can be integrated with the existing clinical outcomes.

In addition to RCT data, it is of interest to note that there is an increased interest in using real world data to support regulatory decision‐making---including the EAU guidelines. Information about how a patient feels and functions, as captured directly from patients themselves, is however also often missing in real world data (eg observational data or hospital data). For example, PROs were only collected in 14% of recent postauthorisation safety studies.[^23^](#cam43018-bib-0023){ref-type="ref"} Harnessing the patient voice through the use PROs in "big data" indeed implies the need to align PRO measurements (PROMs) between RCTs and real world data.[^24^](#cam43018-bib-0024){ref-type="ref"}

With respect to the methodological assessment of PRO use in PCa RCTs, data from this study suggests that completeness of PRO reporting has improved over the last years, as documented by the higher proportion of high‐quality RCTs published from 2012 onward. Indeed, while only 20% of PCa RCTs published between 2004 and 2012 were considered as high quality, this percentage has more than doubled for the more recent RCTs. This may be partly explained by the publication of the ISOQOL recommended standards[^10^](#cam43018-bib-0010){ref-type="ref"} and the subsequent CONSORT‐PRO criteria[^11^](#cam43018-bib-0011){ref-type="ref"} in 2013, which may have guided and helped investigators to increase the completeness of PRO reporting. Indeed, journal endorsement and author use of CONSORT‐PRO extension has been demonstrated to be associated with improved PRO reporting.[^25^](#cam43018-bib-0025){ref-type="ref"}

This study has limitations. First, despite our comprehensive search strategy, it is possible that some RCTs with a PRO component might have been missed. Another limitation is the exclusion of non‐English language published papers. However, it is unlikely that such omission would have significantly altered the conclusion of this review.[^26^](#cam43018-bib-0026){ref-type="ref"} A strength of the current review is that we used a formal, replicable approach to evaluate PRO reporting of PCa RCTs. Since all studies use different reporting criteria and methods, the information was extracted and assessed by two independent researchers. In case of inconsistencies, a third arbiter helped achieving consensus. Also, by using state of the art and well‐established international recommendations for PRO reporting, we were able to identify the proportion of studies that are most likely to robustly inform patient care.

5. CONCLUSION {#cam43018-sec-0013}
=============

We observed an important improvement in the reporting of the evidence for PROs during the last 7 years, of which only a small proportion of high‐quality PRO trials made it into the EAU PCa Guidelines. The most commonly used measurements focused on overall HRQoL and were predominantly used in RCTs of men with advanced PCa, whereas for RCTs in men with localized PCa the focus was more on adverse effects. Given the increasing recognition that the patients' voice in clinical research needs to be heard, there is a need for better guidance as to how to include and measure PRO in "big data" and guidelines---an answer which may be delivered by the EAU‐led PIONEER Consortium.
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